Sam Brusco, Associate Editor09.07.23
alveofit, a company specializing in digital respiratory therapeutics, has earned U.S. Food and Drug Administration (FDA) clearance for its alveoair spirometer.
The company said the portable alveoair digital spirometer can offer real-time insights to enable timely interventions in respiratory care. These insights can lead to predictive analytics in tandem with artificial intelligence (AI) models into respiratory health.
alveofit has previously partnered with pharmaceutical giant AstraZeneca. The company said Dr. Anil Kukreja, VP of medical affairs and regulatory at AstraZeneca Pharma India, praised the FDA clearance as a milestone, highlighting alveofit's role in optimized diagnosis and management of lung disorders like asthma and COPD.
Since achieving CDSCO certification in India in June 2022, alveoair has been adopted by more than 400 healthcare facilities across India. alveofit has also partnered with India Sweden Innovation Centre (ISIHC), NASSCOM COE, PATH, Forge Innovation & Ventures, and DST.
"It is good to see the product mature over the last couple of years and gain acceptance among the providers. I congratulate and wish alveofit a global success with recent approval from FDA, making a difference in the lives of people in India and world over," Sanjeev Malhotra, CEO, NASSCOM COE, told the press.
alveofit also inaugurated its New York office this year.
The company said the portable alveoair digital spirometer can offer real-time insights to enable timely interventions in respiratory care. These insights can lead to predictive analytics in tandem with artificial intelligence (AI) models into respiratory health.
alveofit has previously partnered with pharmaceutical giant AstraZeneca. The company said Dr. Anil Kukreja, VP of medical affairs and regulatory at AstraZeneca Pharma India, praised the FDA clearance as a milestone, highlighting alveofit's role in optimized diagnosis and management of lung disorders like asthma and COPD.
Since achieving CDSCO certification in India in June 2022, alveoair has been adopted by more than 400 healthcare facilities across India. alveofit has also partnered with India Sweden Innovation Centre (ISIHC), NASSCOM COE, PATH, Forge Innovation & Ventures, and DST.
"It is good to see the product mature over the last couple of years and gain acceptance among the providers. I congratulate and wish alveofit a global success with recent approval from FDA, making a difference in the lives of people in India and world over," Sanjeev Malhotra, CEO, NASSCOM COE, told the press.
alveofit also inaugurated its New York office this year.